Nadler Financial Group, Inc. Moderna, Inc. Transaction History

Nadler Financial Group, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 26, 2024	SELL	$85.37 - $115.44 $8,707 - $11,774	-102 Reduced 4.7%	2,070 $220,000
Q3 2023 Oct 24, 2023	BUY	$96.41 - $126.61 $2,410 - $3,165	25 Added 1.16%	2,172 $224,000
Q2 2023 Jul 31, 2023	BUY	$118.5 - $160.53 $99,066 - $134,203	836 Added 63.77%	2,147 $260,000
Q1 2023 Apr 19, 2023	SELL	$135.66 - $197.02 $13,566 - $19,702	-100 Reduced 7.09%	1,311 $201,000
Q4 2022 Jan 30, 2023	BUY	$118.38 - $210.04 $167,034 - $296,366	1,411 New	1,411 $253,000
Q2 2022 Jul 20, 2022	SELL	$117.13 - $176.59 $151,683 - $228,684	-1,295 Closed	0 $0
Q1 2022 May 05, 2022	SELL	$126.46 - $235.05 $112,802 - $209,664	-892 Reduced 40.79%	1,295 $223,000
Q4 2021 Jan 18, 2022	SELL	$225.82 - $368.51 $70,004 - $114,238	-310 Reduced 12.41%	2,187 $555,000
Q3 2021 Oct 13, 2021	SELL	$221.9 - $484.47 $1,109 - $2,422	-5 Reduced 0.2%	2,497 $961,000
Q2 2021 Jul 16, 2021	BUY	$129.91 - $234.98 $20,785 - $37,596	160 Added 6.83%	2,502 $588,000
Q4 2020 Jan 26, 2021	BUY	$65.74 - $169.86 $153,963 - $397,812	2,342 New	2,342 $245,000

954

241M

10.6M

18.7M

Ticker MRNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 391,200,000
Market Cap $14.4B
Description
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...

Get notified when there are updates to the investment portfolio of Nadler Financial Group, Inc., based on Form 13F filings with the SEC.

Stay updated on Nadler Financial Group, Inc. with notifications on news.